黑料网

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

• Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted share
• Entered into an asset purchase agreement to acquire Increlex庐 (mecasermin injection)
• Q3 2024 product sales increased 40% over Q3 2023, representing 15^th straight quarter of sequential product sales growth
• Produced positive quarterly GAAP net income from product sales for first time in company history
• Generated cash from operations of $2.9 million in Q3 2024
• Granted additional patent for ET-400
• Management to hold conference call today at 4:30pm ET
  

DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (鈥淓ton鈥� or 鈥渢he Company鈥�) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2024.

鈥淥ur strong product revenue growth in the third quarter allowed us to achieve positive GAAP net income from product revenue for the first time in the Company鈥檚 history and we鈥檙e pleased to reach this important milestone one quarter ahead of our original goal. We are proud of our ability to continue delivering exceptional growth, as demonstrated by our 15^th straight quarter of sequential growth in product revenue, while managing the bottom line,鈥� said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

鈥淭his milestone is just the beginning of Eton鈥檚 growth story. With the upcoming close of the Increlex acquisition and our ET-400 PDUFA date approaching, 2025 is shaping up to be a transformational year for Eton. We are very excited about what we can achieve in the coming quarters and years,鈥� concluded Brynjelsen.

Third Quarter and Recent Business Highlights

Delivered 15^th straight quarter of sequential growth in product sales and reported positive GAAP net income. Eton reported third quarter 2024 product sales of $9.8 million, representing 40% growth over the prior year period, and 8% over the second quarter of 2024, driven primarily by the ongoing growth of ALKINDI SPRINKLE庐 and Carglumic Acid. During the quarter, Eton produced positive GAAP net income for the first time in Company history from product revenue alone.

Entered into an asset purchase agreement to acquire Increlex庐 (mecasermin injection) from Ipsen S.A. The transaction, which was announced in October, will add a high-value biologic product to the Company鈥檚 commercial portfolio. The product is synergistic with Eton鈥檚 existing pediatric endocrinology call point, and the acquisition is expected to be accretive to 2025 earnings. The Company anticipates the transaction closing near year-end 2024.

New Drug Application (NDA) for ET-400 accepted by the U.S. Food and Drug Administration (FDA). In July, the FDA accepted Eton鈥檚 NDA for ET-400, its proprietary patented formulation of hydrocortisone oral solution and assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025. Eton expects to manufacture product inventory in the fourth quarter of 2024 to enable a commercial launch promptly after the expected approval in 2025. The Company believes the introduction of ET-400 will enable it to capture a greater percentage of the oral hydrocortisone market and, together with ALKINDI SPRINKLE, the two products are expected to achieve combined peak sales of more than $50 million annually.

Granted additional patent for ET-400. On November 5, Eton was granted an additional patent for ET-400 by the United States Patent & Trademark Office (USPTO), further strengthening the IP protection for the product. The patent, which expires in 2043, covers hydrocortisone oral liquid formulations and is expected to be listed in the FDA鈥檚 Orange Book upon ET-400鈥檚 approval.

Strong growth of ALKINDI SPRINKLE and the Company鈥檚 metabolic portfolio. ALKINDI SPRINKLE reported 55% year-over-year revenue growth in Q3 2024. Carglumic Acid also reported another quarter of strong sequential and year-over-year growth. The commercial availability of Betaine Anhydrous, Nitisinone, and PKU GOLIKE庐 has helped increase the frequency of the Company鈥檚 interactions with potential Carglumic Acid prescribers.

Initiation of ET-600 pivotal study. ET-600鈥檚 pivotal bioequivalence study has been initiated. ET-600 is under development for the treatment of the pediatric endocrinology condition diabetes insipidus. If the study results are positive, Eton anticipates submitting an NDA for the product in the first quarter of 2025.

Third Quarter Financial Results

Net Revenue: Net sales for the third quarter of 2024 were $10.3 million compared to $7.0 million in the prior year period. Net sales in the current year period included $0.5 million of licensing payments received from out-licensing of the company鈥檚 DS-200 product.

Product sales and royalty revenue were $9.8 million for the third quarter of 2024, an increase of 40% compared to $7.0 million in the prior year period, and an increase of 8% over the second quarter of 2024. The year-over-year increase in product sales revenue was primarily driven by growth in ALKINDI SPRINKLE and Carglumic Acid.

Gross Profit: Gross profit for the third quarter of 2024 was $6.3 million compared to $4.4 million in the prior year period.

Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2024 were $0.5 million compared to $0.6 million in the prior year period as a result of decreased expenses associated with ET-400 project development activities.

General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2024 were $5.3 million compared to $4.3 million in the prior year period, mainly due to increased sales and marketing activities, legal expenses, and employee-related expenses.

Net Income: Net income for the third quarter of 2024 was $0.6 million or $0.02 per basic and diluted share. In the prior year period, net loss was $0.6 million, or $0.02 per basic and diluted share.

Cash Position: As of September 30, 2024, Eton had cash and cash equivalents of $20.3 million. The Company generated $2.9 million of operating cash flow during the quarter. The Company expects to generate positive cash flow in the fourth quarter and to fund its acquisition of Increlex with cash on hand and an expansion of its existing credit facility.

Conference Call and Webcast Information

As previously announced, Eton Pharmaceuticals will host a its third quarter 2024 conference call as follows:

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: .

The live webcast can also be accessed on the Investors section of Eton鈥檚 website at . An archived webcast will be available on Eton鈥檚 website approximately two hours after the completion of the event and for 30 days thereafter.

About听Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE庐, PKU GOLIKE庐, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO庐 hydrocortisone autoinjector. For more information, please visit our website at听.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton鈥檚 business strategy, Eton鈥檚 plans to develop and commercialize its product candidates, the safety and efficacy of Eton鈥檚 product candidates, Eton鈥檚 plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton鈥檚 product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 鈥渂elieves,鈥� 鈥渁nticipates,鈥� 鈥減lans,鈥� 鈥渆xpects,鈥� 鈥渋ntends,鈥� 鈥渨ill,鈥� 鈥済oal,鈥� 鈥減otential鈥� and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton鈥檚 current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton鈥檚 development programs and financial position are described in additional detail in Eton鈥檚 filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: